Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib and Pembrolizumab in Metastatic Colorectal or Gastric Cancer
NCT03724851Phase 2Completed
- Sponsor
- MedPacto
- Start
- Dec 2018
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vactosertib in metastatic colorectal cancer (mCRC), gastric cancer (GC) and gastroesophageal junction adenocarcinoma (3 arms), sponsored by MedPacto. Primary endpoints: Maximum Tolerated Dose at 2 years and Safety and Tolerability at 2 years. Started Dec 2018; status: completed.
02
Drugs
vactosertib
03
Conditions
metastatic colorectal cancer (mCRC)gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03724851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724851.